Back to search

Article

Longitudinal Changes in Utilities and HRQoL During Interferon‑Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‑Utility Analysis

2026-01-29

Abstract excerpt

<h4>Background: </h4> /Objectives: Direct‑acting antivirals (DAAs) cure hepatitis C virus (HCV) infection and may improve health‑related quality of life (HRQoL), but responsiveness differs across instruments. We quantified longitudinal changes using EQ‑5D‑5L, SF‑8 and CLDQ in a multicenter Japanese cohort. <h4>Methods:</h4> Adults with chronic HCV completed patient‑reported outcomes (PROs) at baseline and 12/24/36...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ba6f442f-b5c9-5b21-9d89-2bb4fe5ee5e8
DOI
10.20944/preprints202601.2245.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Longitudinal Changes in Utilities and HRQoL During Interferon‑Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‑Utility AnalysisDOI 10.20944/preprints202601.2245.v1
Health-related quality of life and associated factors among patients with liver cancerSemantic proximity
Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.Semantic proximity
Impact of Sofosbuvir and Daclastavir on Health-related Quality of Life in Patients Co-infected With Hepatitis C and Human Immunodeficiency VirusSemantic proximity
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.Semantic proximity
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.Semantic proximity
Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness resultsSemantic proximity
Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.Semantic proximity
Impact of influenza-like illnesses on health-related quality of life among Japanese children and adultsSemantic proximity
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.Semantic proximity
Health Utility Measurement with Index Scores for People Living with HIV/AIDS Under Combined Antiretroviral Therapy: A Comparison of EQ-5D-5L and SF-6DSemantic proximity
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.Semantic proximity
Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.Semantic proximity
Select a neighboring publication to make it the new centre.